Jerome HC and Sophia C
Volume7-Issue2
Dates: Received: 2026-01-31 | Accepted: 2026-02-08 | Published: 2026-02-11
Pages: 1-5
Abstract
Background: Many chronic conditions that frequently cause pain in certain areas of the body seem to be related to the infiltration of unwanted irritants across a mucosal barrier in certain tissues that have been weakened by genetic, traumatic, or infection factors. They all have in common that they are ameliorated following treatment with dopaminergic agonists. In the large majority of case reports, the patients were treated with the dopamine agonist Dextroamphetamine Sulfate (DS). However, the dopamine agonist cabergoline (Typically used to treat galactorrhea or prolactinomas) has also been successful in eradicating refractory pain syndromes. One pain syndrome that has been successfully eradicated by dopamine agonists is the Burning Mouth Syndrome (BMS). There is one case report showing great efficacy of treating BMS (Stomatodynia) with DS. The case reported here presents the second case of BMS completely eradicated by treatment with a dopamine agonist.
Methods: A 44-year-old woman had multiple pathological symptoms including a very painful tongue and palate with no visible lesions. She previously had a history of Premature Ventricular Contractions (PVCs). She was initially prescribed amphetamines, but it was stopped because she thought it increased the frequencies of PVCs. She was then treated with cabergoline. 0.5 mg two times per week
Results: Within one month her primary BMS was completely eradicated. She has been free of BMS for 4 years.
Conclusion: This is the second case of marked amelioration of BMS following the treatment with a dopamine agonist. It is the first case of eradication of BMS with the sole treatment with the dopamine agonist cabergoline.
FullText HTML
FullText PDF
DOI: 10.37871/jbres2266
Certificate of Publication
Copyright
© 2026 Jerome HC, et al. Distributed under Creative Commons CC-BY 4.0 
How to cite this article
Jerome HC, Sophia C. Marked Relief of Pain from Burning Mouth Syndrome Following Treatment with the Dopamine Agonist Cabergoline-Case Report. J Biomed Res Environ Sci. 2026 Feb 11; 7(2): 5. Doi: 10.37871/jbres2266
Subject area(s)
References
- Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med. 2003;14(4):275-91. doi: 10.1177/154411130301400405. PMID: 12907696.
- International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia. 2020 Feb;40(2):129-221. doi: 10.1177/0333102419893823. PMID: 32103673.
- Kohorst JJ, Bruce AJ, Torgerson RR, Schenck LA, Davis MDP. The prevalence of burning mouth syndrome: a population-based study. Br J Dermatol. 2015 Jun;172(6):1654-1656. doi: 10.1111/bjd.13613. Epub 2015 Apr 29. PMID: 25495557; PMCID: PMC4456238.
- Renton T. Burning mouth syndrome. Rev Pain. 2011;5(4): 12-17. DOI: 10.1177/204946371100500403.
- Bergdahl M, Bergdahl J. Burning mouth syndrome: prevalence and associated factors. J Oral Pathol Med. 1999 Sep;28(8):350-4. doi: 10.1111/j.1600-0714.1999.tb02052.x. PMID: 10478959.
- Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia. 2022 Feb;42(2):128-161. doi: 10.1177/03331024211036152. Epub 2021 Aug 18. PMID: 34404247; PMCID: PMC8793318.
- Grinspan D, Blanco GF, Allevato MA, Stengel FM. Burning mouth syndrome. International Journal of Dermatology. 1995;34(7):483-487. doi : 10.1111/j.1365-4362.1995.tb00617.x.
- Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: clinical features. J Orofac Pain. 1999 Summer;13(3):172-84; discussion 185-95. PMID: 10823031.
- Check JH, Neumann B, Check DL. New insight into the etiology and treatment of the vulvostomatodynia and review of treating pelvic pain with dopaminergic drugs. Gynecol Reprod Health. 2024;8(4):1-8. doi: 10.33425/2639-9342.1257.
- Check JH, Cohen R, Katsoff B, Check D. Hypofunction of the sympathetic nervous system is an etiologic factor for a wide variety of chronic treatment-refractory pathologic disorders which all respond to therapy with sympathomimetic amines. Med Hypotheses. 2011 Nov;77(5):717-25. doi: 10.1016/j.mehy.2011.07.024. Epub 2011 Aug 10. PMID: 21835553.
- Check DL, Check JH. Various presentations of the increased cellular permeability syndrome in males responding very well to sympathomimetic amine therapy - possible treatment for end-stage Covid-19 complications. J Med Clin Res & Rev. 2020; (7):1-7.
- Check JH. Most chronic conditions in women are related to increased cellular permeability and most can be effectively treated with dopaminergic drugs. J Biomed Res Environ Sci. 2024;5(4):373-386. doi: 10.37871/jbres1903.
- Check JH. Changing the name of a syndrome: Sympathetic neural hyperalgesia edema syndrome becomes - the increased cellular permeability syndrome. Clin Exp Obstet Gynecol. 2017;44:819-823. doi: 10.12891/ceog3883.2017.
- Check JH. Studies of mechanisms involved in successful embryo implantation has led to novel highly effective treatments for a plethora of chronic illnesses and advanced cancer.Am J Biomed Sci & Res. 2025;25(4). doi: 10.34297/A.JBSR.2025.25.003349.
- Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). J Orofac Pain. 2009 Summer;23(3):202-10. PMID: 19639097.
- Check JH, Check D. Improvement of severe chronic pelvic pain and dysmenorrhea following treating with cabergoline. Gynecol Reprod Health. 2023; 7(1): 1-6. doi: 10.33425/2639-9342.1216.
- Check JH, Check DL, Neumann B. Marked improvement of severe treatment resistant migraine headaches with the dopaminergic drug cabergoline. J Med-Clin Res&Rev. 2024; 8(3):1-5. doi: 10.33425/2639-944X.1368.
- Check JH, Lombardi G, Javier J. Two new clinical manifestations of the increased cellular permeability syndrome responding well to dopaminergic drugs; carpel tunnel syndrome, and sesamoiditis. Bio Med Res J. 2024;8(3):814-818.
- Check JH, McDonald O'Neil M, Neulander M, Check DL. Dopaminergic drug combination for stomatodynia eliminates tardive dyskinesia resulting from higher dosages of dextroamphetamine, J Clinical Research and Reports. 2025;18(3). doi: 10.31579/2690-1919/436.
- Check JH, Liss J, Check D. The beneficial effect of luteal phase support on pregnancy rates in women with unexplained infertility. Clin Exp Obstet Gynecol. 2019;46(3):447-449.
- Check JH, Cohen R. Sympathetic neural hyperalgesia edema syndrome, a frequent cause of pelvic pain in women, mistaken for Lyme disease with chronic fatigue. Clin Exp Obstet Gynecol. 2011;38(4):412-3. PMID: 22268288.
- Check DL, Check JH, Katsoff B. Dextroamphetamine sulfate therapy markedly improves the chronic fatigue syndrome. J Nurs Occup Health. 2020;2(3):146-148.
- Check DL, Check JH, Citerone T, Cremin N. Sympathomimetic amine therapy markedly improves severe fatigue that diminishes quality of life in patients with cancer - A case report. Cancer Sci Res. 2020;3(3):1-3. doi: 10.33425/2639-8478.1054
- Check JH, Shanis BS, Shapse D, Adelson HG. A randomized comparison of the effect of two diuretics, a converting enzyme inhibitor, and a sympathomimetic amine on weight loss in diet-refractory patients. Endocr Pract. 1995 Sep-Oct;1(5):323-6. doi: 10.4158/EP.1.5.323. PMID: 15251577.
- Check JH, Check D, Liss JR. Effect of treatment with dextroamphetamine sulfate on weight loss up to 5 years in women unable to lose weight by dieting and its efficacy on some other unusual manifestations of the increased cellular permeability syndrome. J Med Clin Res & Rev. 2021;5:1-5. doi: 10.33425/2639-944X.1209.
- Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Någren K, Jääskeläinen S. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain. 2003 Jan;101(1-2):149-54. doi: 10.1016/s0304-3959(02)00323-8. PMID: 12507709.
- Check JH, Srivastava P, Kelley C. The relative efficacy of three different dopamine agonists in relieving symptoms of various manifestations of the increased cellular permeability syndrome. Case report. Int J Clin Med Case Stud. 2025;2(2):1039.